Practical guide to prevention of contrast-induced acute kidney injury after percutaneous coronary intervention.
PCI complications
acute renal disease
contrast agents
percutaneous coronary intervention
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
15 02 2021
15 02 2021
Historique:
received:
22
10
2019
revised:
12
12
2019
accepted:
11
01
2020
pubmed:
23
1
2020
medline:
25
9
2021
entrez:
23
1
2020
Statut:
ppublish
Résumé
Contrast-induced acute kidney injury (CI-AKI) represents a common but serious complication of percutaneous coronary interventions (PCI)-and in general of all those examinations requiring iodinated contrast injection-which affects not only renal function but also long-term prognosis. While several prophylactic approaches were designed in order to prevent CI-AKI, most failed to demonstrate clear benefits in randomized trials, and their implementation is therefore discouraged in clinical practice. The most notorious examples include pre-procedural bicarbonate or N-acetylcysteine, and preprocedural withdrawal of ACE inhibitors/Angiotensin receptor blockers. Those strategies that were instead demonstrated effective include the appropriate use of preprocedural hydration, reduction in contrast volume utilization, adoption of techniques for zero- or ultra-low-contrast procedures, and pharmacological treatments with statins. In this brief review, we summarize the main preventive strategies into brief and pragmatic recommendations designed to improve everyday clinical practice.
Substances chimiques
Contrast Media
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
443-450Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Kellum JA, Lameire N, KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (part 1). Crit Care. 2013;17(1):204.
Guillon B, Ecarnot F, Marcucci C, et al. Incidence, predictors and impact on 6 month mortality of three different definitions of contrast-induced acute kidney injury after coronary angiography. Am J Cardiol. 2018;121(7):818-824.
Schmucker J, Fach A, Becker M, et al. Predictors of acute kidney injury in patients admitted with ST-elevation myocardial infarction - results from the Bremen STEMI-registry. Eur Heart J Acute Cardiovasc Care. 2018;7(8):710-722.
McCullough PA, Choi JP, Feghali GA, et al. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2016;68(13):1465-1473.
Marenzi G, Lauri G, Assanelli E, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2004;44(9):1780-1785.
Mehran R, George D, Steven D, Weisbord MD. Contrast-associated acute kidney injury. N Engl J Med. 2019;380:2146-2155.
Tsai TT, Patel UD, Chang TI, et al. Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry. JACC Cardiovasc Interv. 2014;7(1):1-9.
Rear R, Bell RM, Hausenloy DJ. Contrast-induced nephropathy following angiography and cardiac interventions. Heart. 2016;102:638-648.
Seeliger E, Sendeski M, Rihal CS, Persson PB. Contrast-induced kidney injury: mechanisms, risk factors, and prevention. Eur Heart J. 2012;33(16):2007-2015.
Maioli M, Toso A, Leoncini M, Gallopin M, Musilli N, Bellandi F. Persistent renal damage after contrast-induced acute kidney injury: incidence, evolution, risk factors, and prognosis. Circulation. 2012;125:3099-3107.
Andreis A, Budano C, Levis M, et al. Contrast-induced kidney injury: how does it affect long-term cardiac mortality? J Cardiovasc Med (Hagerstown). 2017;18(11):908-915.
Abe M, Morimoto T, Nakagawa Y, et al. Impact of transient or persistent contrast induced nephropathy on long-term mortality after elective percutaneous coronary intervention. Am J Cardiol. 2017;120:2146-2153.
Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44:1393-1399.
Tsai TT, Patel UD, Chang TI, et al. Validated contemporary risk model of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the National Cardiovascular Data Registry Cath-PCI registry. J Am Heart Assoc. 2014;3(6):e001380.
Weisbord SD, Gallagher M, Jneid H, et al. Outcomes after angiography with sodium bicarbonate and Acetylcysteine. N Engl J Med. 2018;378(7):603-614.
Brueck M, Cengiz H, Hoeltgen R, et al. Usefulness of N-acetylcysteine or ascorbic acid versus placebo to prevent contrast-induced acute kidney injury in patients undergoing elective cardiac catheterization: a single center, prospective, double-blind, placebo-controlled trial. J Invasive Cardiol. 2013;25:276-283.
Li R, Chen H. Prevention of contrast-induced nephropathy with ascorbic acid. Heart. 2012;98:E211.
Sadat U, Usman A, Gillard JH, Boyle JR. Does ascorbic acid protect against contrast-induced acute kidney injury in patients undergoing coronary angiography: a systematic review with meta-analysis of randomized, controlled trials. J Am Coll Cardiol. 2013;62(23):2167-2175.
Bainey KR, Rahim S, Etherington K, et al. Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: results from the angiotensin converting enzyme inhibitor/angiotensin receptor blocker and contrast induced nephropathy in patients receiving cardiac catheterization (CAPTAIN) trial. Am Heart J. 2015;170(1):110-116.
Whiting P, Morden A, Tomlinson LA, et al. What are the risks and benefits of temporarily discontinuing medications to prevent acute kidney injury? A Systematic Review and Meta-Analysis BMJ Open. 2017;7:e012674.
Zeller M, Labalette-Bart M, Juliard JM, et al. Metformin and contrast-induced acute kidney injury in diabetic patients treated with primary percutaneous coronary intervention for ST segment elevation myocardial infarction: a multicenter study. Int J Cardiol. 2016;220:137-142.
Lal A, Kaur N, Trivedi N. Metformin, arterial contrast and acute kidney injury. Acta Biomed. 2019;90(2):355-356.
Pandya B, Chalhoub JM, Parikh V, et al. Contrast media use in patients with chronic kidney disease undergoing coronary angiography: a systematic review and meta-analysis of randomized trials. Int J Cardiol. 2017;228:137-144.
Neumann FJ, Sousa-Uva M, Ahlsson A, et al. ESC scientific document group 2018. ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2018;40(2):87-165.
Marenzi G, Lauri G, Campodonico J, et al. Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. Am J Med. 2006;119:155-162.
Cruz DN, Goh CY, Marenzi G, Corradi V, Ronco C, Perazella MA. Renal replacement therapies for prevention of radiocontrast-induced nephropathy: a systematic review. Am J Med. 2012;125:66-78.
Van der Molen AJ, Reimer P, Dekkers IA, et al. Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients: recommendations for updated ESUR contrast medium safety committee guidelines. Eur Radiol. 2018 Jul;28(7):2856-2869.
Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med. 2002;162:329-336.
Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/ SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58:e44-e122.
Brar SS, Aharonian V, Mansukhani P, et al. Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial. Lancet. 2014;383(9931):1814-1823.
Qian G, Fu Z, Guo J, Cao F, Chen Y. Prevention of contrast-induced nephropathy by central venous pressure-guided fluid administration in chronic kidney disease and congestive heart failure patients. JACC Cardiovasc Interv. 2016;9:89-96.
Maioli M, Toso A, Leoncini M, et al. Bioimpedance-guided hydration for the prevention of contrast-induced kidney injury. J Am Coll Cardiol. 2018;71(25):2880-2889.
Marenzi G, Ferrari C, Marana I, et al. Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (induced diuresis with matched hydration compared to standard hydration for contrast induced nephropathy prevention) trial. JACC Cardiovasc Interv. 2012 Jan;5(1):90-97.
Briguori C, Visconti G, Focaccio A, et al. Condorelli G; REMEDIAL II investigators. Renal insufficiency after contrast media administration trial II (REMEDIAL II): RenalGuard system in high-risk patients for contrast-induced acute kidney injury. Circulation. 2011;124(11):1260-1269.
Briguori C, D'Amore C, De Micco F, et al. REMEDIAL III Investigators. Renal insufficiency following contrast media administration trial III: urine flow rate-guided versus left-ventricular enddiastolic pressure-guided hydration in high-risk patients for contrast-induced acute kidney injury. Rationale and design. Catheter Cardiovasc Interv. 2019. https://doi.org/10.1002/ccd.28386. [Epub ahead of print].
Chen S, Liu Y, Bei W, et al. Optimal hydration volume among high-risk patients with advanced congestive heart failure undergoing coronary angiography. Oncotarget. 2018;9(34):23738-23748.
Liu Y, Li H, Chen S, et al. Excessively high hydration volume may not be associated with decreased risk of contrast-induced acute kidney injury after percutaneous coronary intervention in patients with renal insufficiency. J Am Heart Assoc. 2016;5:e003171.
Desch S, Fuernau G, Pöss J, et al. Impact of a novel contrast reduction system on contrast savings in coronary angiography - the DyeVert randomised controlled trial. Int J Cardiol. 2018;257:50-53.
Mehran R, Faggioni M, Chandrasekhar J, et al. Effect of a contrast modulation system on contrast media use and the rate of acute kidney injury after coronary angiography. JACC Cardiovasc Interv. 2018;11(16):1601-1610.
Tunuguntla A, Daneault B, Kirtane AJ. Novel use of the GuideLiner catheter to minimize contrast use during PCI in a patient with chronic kidney disease. Catheter Cardiovasc Interv. 2012;80:453-455.
Mariani J, Guedes C, Soares P, et al. Intravascular ultrasound guidance to minimize the use of iodine contrast in percutaneous coronary intervention. JACC Cardiovasc Interv. 2014;7(11):1287-1293.
Azzalini L, Mitomo S, Hachinohe D, Regazzoli D, Colombo A. Zero-contrast percutaneous coronary intervention guided by dextran-based optical coherence tomography. Can J Cardiol. 2018;34(3):342.e1-342.e342.
Flaherty MP, Moses JW, Westenfeld R, et al. Impella support and acute kidney injury during high-risk percutaneous coronary intervention: the global cVAD renal protection study. Catheter Cardiovasc Interv. 2019. https://doi.org/10.1002/ccd.28400. [Epub ahead of print].
Andò G, Cortese B, Russo F, et al. MATRIX investigators. Acute kidney injury after radial or femoral access for invasive acute coronary syndrome management: AKI-MATRIX. J Am Coll Cardiol. 2017;69(21):2592-2603.
Andò G, Costa F, Trio O, Oreto G, Valgimigli M. Impact of vascular access on acute kidney injury after percutaneous coronary intervention. Cardiovasc Revasc Med. 2016;17(5):333-338.
Almendarez M, Gurm HS, Mariani J Jr, et al. Procedural strategies to reduce the incidence of contrast-induced acute kidney injury during percutaneous coronary intervention. JACC Cardiovasc Interv. 2019;12(19):1877-1888.
Gurm HS, Seth M, Dixon SR, et al. Contemporary use of and outcomes associated with ultra-low contrast volume in patients undergoing percutaneous coronary interventions. Catheter Cardiovasc Interv. 2019;93:222-230.
Azzalini L, Laricchia A, Regazzoli D, et al. Ultra-low contrast percutaneous coronary intervention to minimize the risk for contrast-induced acute kidney injury in patients with severe chronic kidney disease. J Invasive Cardiol. 2019;31(6):176-182.
Nayak KR, Mehta HS, Price MJ, et al. A novel technique for ultra-low contrast administration during angiography or intervention. Catheter Cardiovasc Interv. 2010;75:1076-1083.
Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: results from the PRATO-ACS study (protective effect of Rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome). J Am Coll Cardiol. 2014;63:71-79.
Marenzi G, Cosentino N, Werba JP, Tedesco CC, Veglia F, Bartorelli AL. A meta-analysis of randomized controlled trials on statins for the prevention of contrast-induced acute kidney injury in patients with and without acute coronary syndromes. Int J Cardiol. 2015 Mar 15;183:47-53.
Han Y, Zhu G, Han L, et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol. 2014;63(1):62-70.
Giacoppo D, Gargiulo G, Buccheri S, et al. Preventive strategies for contrast-induced acute kidney injury in patients undergoing percutaneous coronary procedures: evidence from a hierarchical Bayesian network meta-analysis of 124 trials and 28 240 patients. Circ Cardiovasc Interv. 2017;10:e004383.
Akyuz S, Yaylak B, Altay S, Kasikcioglu H, Cam N. The role of statins in preventing contrast-induced acute kidney injury: a narrative review. Angiology. 2015;66(8):701-707.
Li H, Wang C, Liu C, Li R, Zou M, Cheng G. Efficacy of Short-term statin treatment for the prevention of contrast-induced acute kidney injury in patients undergoing coronary angiography/percutaneous coronary intervention: a meta-analysis of 21 randomized controlled trials. Am J Cardiovasc Drugs. 2016;16(3):201-219.